The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Peptide Based Metabolic Disorders Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability.
The global Peptide Based Metabolic Disorders Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Based Metabolic Disorders Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Peptide Based Metabolic Disorders Therapeutics market. Exenatide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Liraglutide segment is estimated at % CAGR for the next seven-year period.
North America is expected to dominate the global market in terms of higher market share.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Based Metabolic Disorders Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Based Metabolic Disorders Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Based Metabolic Disorders Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Based Metabolic Disorders Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Based Metabolic Disorders Therapeutics covered in this report include AstraZeneca, Ingro Finanz (Bachem), Eli Lilly, Ipsen, Merck, Novo Nordisk, PolyPeptide Group and Teva Pharmaceutical, etc.
The global Peptide Based Metabolic Disorders Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Ingro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical
Global Peptide Based Metabolic Disorders Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Based Metabolic Disorders Therapeutics market, Segment by Type:
Exenatide
Liraglutide
Others
Global Peptide Based Metabolic Disorders Therapeutics market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Peptide Based Metabolic Disorders Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability.
The global Peptide Based Metabolic Disorders Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Based Metabolic Disorders Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Peptide Based Metabolic Disorders Therapeutics market. Exenatide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Liraglutide segment is estimated at % CAGR for the next seven-year period.
North America is expected to dominate the global market in terms of higher market share.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Based Metabolic Disorders Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Based Metabolic Disorders Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Based Metabolic Disorders Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Based Metabolic Disorders Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Based Metabolic Disorders Therapeutics covered in this report include AstraZeneca, Ingro Finanz (Bachem), Eli Lilly, Ipsen, Merck, Novo Nordisk, PolyPeptide Group and Teva Pharmaceutical, etc.
The global Peptide Based Metabolic Disorders Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Ingro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical
Global Peptide Based Metabolic Disorders Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Based Metabolic Disorders Therapeutics market, Segment by Type:
Exenatide
Liraglutide
Others
Global Peptide Based Metabolic Disorders Therapeutics market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Peptide Based Metabolic Disorders Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Peptide Based Metabolic Disorders Therapeutics
1.1 Peptide Based Metabolic Disorders Therapeutics Market Overview
1.1.1 Peptide Based Metabolic Disorders Therapeutics Product Scope
1.1.2 Peptide Based Metabolic Disorders Therapeutics Market Status and Outlook
1.2 Global Peptide Based Metabolic Disorders Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2018-2029)
1.4 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Peptide Based Metabolic Disorders Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Peptide Based Metabolic Disorders Therapeutics Market Size (2018-2029)
1.6.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size (2018-2029)
1.6.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size (2018-2029)
1.6.4 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size (2018-2029)
2 Peptide Based Metabolic Disorders Therapeutics Market by Type
2.1 Introduction
2.1.1 Exenatide
2.1.2 Liraglutide
2.1.3 Others
2.2 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
3 Peptide Based Metabolic Disorders Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Peptide Based Metabolic Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
4 Peptide Based Metabolic Disorders Therapeutics Competition Analysis by Players
4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2022)
4.3 Date of Key Players Enter into Peptide Based Metabolic Disorders Therapeutics Market
4.4 Global Top Players Peptide Based Metabolic Disorders Therapeutics Headquarters and Area Served
4.5 Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Peptide Based Metabolic Disorders Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.1.4 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Ingro Finanz (Bachem)
5.2.1 Ingro Finanz (Bachem) Profile
5.2.2 Ingro Finanz (Bachem) Main Business
5.2.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.2.4 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Ingro Finanz (Bachem) Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.3.4 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Ipsen Recent Developments
5.4 Ipsen
5.4.1 Ipsen Profile
5.4.2 Ipsen Main Business
5.4.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.4.4 Ipsen Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Ipsen Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.5.4 Merck Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Novo Nordisk
5.6.1 Novo Nordisk Profile
5.6.2 Novo Nordisk Main Business
5.6.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.6.4 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Novo Nordisk Recent Developments
5.7 PolyPeptide Group
5.7.1 PolyPeptide Group Profile
5.7.2 PolyPeptide Group Main Business
5.7.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.7.4 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 PolyPeptide Group Recent Developments
5.8 Teva Pharmaceutical
5.8.1 Teva Pharmaceutical Profile
5.8.2 Teva Pharmaceutical Main Business
5.8.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Products, Services and Solutions
5.8.4 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Teva Pharmaceutical Recent Developments
6 North America
6.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Peptide Based Metabolic Disorders Therapeutics Market Dynamics
11.1 Peptide Based Metabolic Disorders Therapeutics Industry Trends
11.2 Peptide Based Metabolic Disorders Therapeutics Market Drivers
11.3 Peptide Based Metabolic Disorders Therapeutics Market Challenges
11.4 Peptide Based Metabolic Disorders Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
